Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has issued 1,020,055 deferred share units (DSUs) to directors of the company per its fixed 10% equity incentive compensation plan.
The developer of barium, iodine and carbon fullerene Active Pharmaceutical Ingredients (APIs) and high-performance, cost-effective imaging contrast agents said the DSUs compensate directors for their annual retainers.
They are issued quarterly using a deemed value equal to the weighted average share price during the quarter, the company said.